Zevra Therapeutics, Inc. (ZVRA)
ZVRA Stock Price Chart
Explore Zevra Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ZVRA price movements and trends.
ZVRA Company Profile
Discover essential business fundamentals and corporate details for Zevra Therapeutics, Inc. (ZVRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Apr 2015
Employees
59.00
Website
https://zevra.comCEO
Neil F. McFarlane
Description
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
ZVRA Financial Timeline
Browse a chronological timeline of Zevra Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 9 Mar 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.04, while revenue estimate is $26.64M.
Earnings released on 12 Aug 2025
EPS came in at $1.21 falling short of the estimated $2.19 by -44.75%, while revenue for the quarter reached $25.88M , beating expectations by +5.56%.
Earnings released on 13 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.21 by +71.43%, while revenue for the quarter reached $20.40M , missing expectations by -3.19%.
Earnings released on 11 Mar 2025
EPS came in at -$0.67 falling short of the estimated -$0.39 by -71.79%, while revenue for the quarter reached $12.04M , missing expectations by -27.73%.
Earnings released on 12 Nov 2024
EPS came in at -$0.69 falling short of the estimated -$0.44 by -56.82%, while revenue for the quarter reached $3.70M , missing expectations by -57.90%.
Earnings released on 13 Aug 2024
EPS came in at -$0.48 falling short of the estimated -$0.47 by -2.13%, while revenue for the quarter reached $4.45M , beating expectations by +2.04%.
Earnings released on 8 May 2024
EPS came in at -$0.40 surpassing the estimated -$0.49 by +18.37%, while revenue for the quarter reached $3.43M , missing expectations by -26.34%.
Earnings released on 28 Mar 2024
EPS came in at -$0.40 falling short of the estimated -$0.20 by -100.00%, while revenue for the quarter reached $13.22M , beating expectations by +12.58%.
Earnings released on 7 Nov 2023
EPS came in at -$0.40 falling short of the estimated -$0.29 by -37.93%, while revenue for the quarter reached $2.90M , missing expectations by -73.56%.
Earnings released on 14 Aug 2023
EPS came in at -$0.15 surpassing the estimated -$0.39 by +61.54%, while revenue for the quarter reached $8.47M , beating expectations by +179.54%.
Earnings released on 15 May 2023
EPS came in at -$0.34 falling short of the estimated -$0.26 by -30.77%, while revenue for the quarter reached $2.88M , beating expectations by +8.64%.
Earnings released on 7 Mar 2023
EPS came in at -$0.26 falling short of the estimated -$0.21 by -23.81%, while revenue for the quarter reached $2.32M , missing expectations by -25.34%.
Earnings released on 9 Nov 2022
EPS came in at -$0.19 falling short of the estimated -$0.13 by -46.15%, while revenue for the quarter reached $2.87M , missing expectations by -4.59%.
Earnings released on 11 Aug 2022
EPS came in at -$0.19 falling short of the estimated -$0.12 by -58.33%, while revenue for the quarter reached $1.30M , missing expectations by -25.61%.
Earnings released on 12 May 2022
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $3.97M , beating expectations by +29.36%.
Earnings released on 30 Mar 2022
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $2.58M , beating expectations by +15.53%.
Earnings released on 10 Nov 2021
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%, while revenue for the quarter reached $1.97M .
Earnings released on 12 Aug 2021
EPS came in at $0.21 falling short of the estimated $0.23 by -8.70%, while revenue for the quarter reached $11.99M .
Earnings released on 13 May 2021
EPS came in at -$0.54 falling short of the estimated -$0.17 by -217.65%, while revenue for the quarter reached $12.12M .
Earnings released on 11 Mar 2021
EPS came in at -$1.07 falling short of the estimated -$0.64 by -67.19%, while revenue for the quarter reached $2.37M .
Stock split effective on 28 Dec 2020
Shares were split 1 : 16 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 29 Oct 2020
EPS came in at -$0.64 surpassing the estimated -$0.80 by +20.00%, while revenue for the quarter reached $1.93M .
ZVRA Stock Performance
Access detailed ZVRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.